A randomized, controlled trial found 4 weeks of pharmaceutical CBD did not significantly improve symptoms in patients with idiopathic or diabetic gastroparesis compared to placebo.
Gastroenterologists, gastroparesis patients, and researchers studying CBD for gastrointestinal conditions.
CBD did not outperform placebo for gastroparesis symptoms over 4 weeks
What the researchers found
Pharmaceutical CBD treatment for 4 weeks did not produce significant improvements in gastroparesis symptoms compared to placebo. Despite CBD's known effects on gut sensation and inflammation, these did not translate to clinical benefit in this patient population.
Why it matters
Gastroparesis is a debilitating condition with limited treatment options. This negative trial is important because it tempers expectations about CBD for gastrointestinal conditions despite mechanistic rationale.
The numbers in context
4 weeks of pharmaceutical CBD treatment. Compared to placebo. No significant improvement in gastroparesis symptoms.
How the study worked
Randomized, controlled trial comparing 4 weeks of pharmaceutical CBD versus placebo in patients with idiopathic or diabetic gastroparesis. Multiple symptom and physiological endpoints assessed.
What this study cannot tell us
Relatively short treatment duration (4 weeks). Specific CBD dose used may not be optimal. Small sample size possible. Gastroparesis symptom measurement is challenging. Does not rule out benefit at different doses or longer treatment durations.
How to read the evidence
Randomized controlled trial with appropriate design. Negative result is informative for clinical decision-making.
When this study was published
Published 2023.
The bigger picture
Negative trials are essential for building an honest evidence base. While CBD has demonstrated gastrointestinal effects in preclinical studies, this trial shows those effects do not automatically translate to symptom improvement in gastroparesis patients.
Questions still open
- Would higher CBD doses or longer treatment produce different results? Are there gastroparesis subtypes that might respond better to CBD?
Common questions
Does CBD help gastroparesis?
Why did CBD not work for gastroparesis despite lab evidence?
Read the original research
A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 21(13), 3405-3414.e4
Citation
Zheng, Ting; BouSaba, Joelle; Taylor, Ann; Dilmaghani, Saam; Busciglio, Irene; Carlson, Paula; Torres, Monique; Ryks, Michael; Burton, Duane; Harmsen, William Scott; Camilleri, Michael. (2023). A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 21(13), 3405-3414.e4. https://doi.org/10.1016/j.cgh.2023.07.008
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk